{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:15:25Z","timestamp":1787170525243,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-026-00425-3","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T13:33:58Z","timestamp":1769261638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comparative assessment of radiochemical purity and yield of [18F]PSMA-1007 production using two different automated synthesis platforms: a head-to-head comparison"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8448-2118","authenticated-orcid":false,"given":"Michela","family":"Cossandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Statuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Migliorati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Luca","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Spiazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Rodella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Camoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Biasiotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"9","key":"425_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1097\/MNM.0000000000002009","volume":"46","author":"MFB Ahmad Fadzil","year":"2025","unstructured":"Ahmad Fadzil MFB, Rohani MFBM, Onny MAA, Ashhar Z, Said MAB, Mahamood M, et al. Synthesis and clinical evaluation of cyclotron-produced [68Ga]PSMA-11 and [18F]PSMA-1007 for prostate cancer imaging. Nucl Med Commun. 2025;46(9):872\u201383. https:\/\/doi.org\/10.1097\/MNM.0000000000002009.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"425_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2174\/092986712799078370","volume":"19","author":"C Ba\u0159inka","year":"2012","unstructured":"Ba\u0159inka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem. 2012;19(6):856\u201370. https:\/\/doi.org\/10.2174\/092986712799078370.","journal-title":"Curr Med Chem"},{"issue":"2","key":"425_CR3","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/curroncol30020178","volume":"30","author":"CV Berenguer","year":"2023","unstructured":"Berenguer CV, Pereira F, C\u00e2mara JS, Pereira JAM. Underlying features of prostate cancer-statistics, risk factors, and emerging methods for its diagnosis. Curr Oncol. 2023;30(2):2300\u201321. https:\/\/doi.org\/10.3390\/curroncol30020178.","journal-title":"Curr Oncol"},{"issue":"3","key":"425_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Sch\u00e4fer M, Benesov\u00e1 M, Bauder-W\u00fcst U, Leotta K, Eder M, et al. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017a;58(3):425\u201331. https:\/\/doi.org\/10.2967\/jnumed.116.181768.","journal-title":"J Nucl Med"},{"issue":"4","key":"425_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/ph10040077","volume":"10","author":"J Cardinale","year":"2017","unstructured":"Cardinale J, Martin R, Remde Y, Sch\u00e4fer M, Hienzsch A, H\u00fcbner S, et al. Procedures for the GMP-compliant production and quality control of [18F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer. Pharmaceuticals (Basel). 2017b;10(4):77. https:\/\/doi.org\/10.3390\/ph10040077.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"19","key":"425_CR6","doi-asserted-by":"publisher","first-page":"10897","DOI":"10.1021\/acs.jmedchem.9b01479","volume":"63","author":"J Cardinale","year":"2020","unstructured":"Cardinale J, Roscher M, Sch\u00e4fer M, Geerlings M, Benesov\u00e1 M, Bauder-W\u00fcst U, et al. Development of PSMA-1007-related series of 18F-labeled Glu-ureido-type PSMA inhibitors. J Med Chem. 2020;63(19):10897\u2013907. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01479.","journal-title":"J Med Chem"},{"issue":"5","key":"425_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/cej.0000000000000960","volume":"34","author":"E Crocetti","year":"2025","unstructured":"Crocetti E, Ravaioli A, Falcini F, Vattiato R, Mancini S, Baldacchini F, et al. The burden of prostate cancer and metastatic prostate cancer in Italy in 2024. Eur J Cancer Prev. 2025;34(5):387\u201391. https:\/\/doi.org\/10.1097\/cej.0000000000000960.","journal-title":"Eur J Cancer Prev"},{"key":"425_CR8","unstructured":"European Pharmacopoeia. Identification and control of residual solvents. 04\/2020:20424. 11th ed. Strasbourg: EDQM Council of Europe; 2020."},{"key":"425_CR9","unstructured":"European Pharmacopoeia. PSMA-1007 (18F) injection. 04\/2024:3116. 11th ed. Strasbourg: EDQM Council of Europe; 2024."},{"key":"425_CR10","unstructured":"European Pharmacopoeia. Gallium (68Ga) PSMA-11 injection. 04\/2021:3044. 11th ed. Strasbourg: EDQM Council of Europe; 2021."},{"key":"425_CR11","unstructured":"European Pharmacopoeia. Osmolality. 01\/2024:20235. 11th ed. Strasbourg: EDQM Council of Europe; 2024."},{"issue":"3","key":"425_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.semnuclmed.2014.03.006","volume":"44","author":"F Fahey","year":"2014","unstructured":"Fahey F, Stabin M. Dose optimization in nuclear medicine. Semin Nucl Med. 2014;44(3):193\u2013201. https:\/\/doi.org\/10.1053\/j.semnuclmed.2014.03.006.","journal-title":"Semin Nucl Med"},{"key":"425_CR13","doi-asserted-by":"publisher","first-page":"3502389","DOI":"10.1155\/2021\/3502389","volume":"2021","author":"M Ferrari","year":"2021","unstructured":"Ferrari M, Treglia G. 18F-PSMA-1007 PET in biochemical recurrent prostate cancer: an updated meta-analysis. Contrast Media Mol Imaging. 2021;2021:3502389. https:\/\/doi.org\/10.1155\/2021\/3502389.","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"425_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41181-019-0086-z","volume":"5","author":"N Gillings","year":"2020","unstructured":"Gillings N, Todde S, Behe M, Decristoforo C, Elsinga P, Ferrari V, et al. EANM guideline on the validation of analytical methods for radiopharmaceuticals. EJNMMI Radiopharm Chem. 2020;5(1):7. https:\/\/doi.org\/10.1186\/s41181-019-0086-z.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"425_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-021-00108-1","volume":"6","author":"N Gillings","year":"2021","unstructured":"Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P, et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021;6(1):8. https:\/\/doi.org\/10.1186\/s41181-021-00108-1.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"425_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.apradiso.2014.04.021","volume":"91","author":"P He","year":"2014","unstructured":"He P, Haswell SJ, Pamme N, Archibald SJ. Advances in processes for PET radiotracer synthesis: separation of [18F]fluoride from enriched [18O]water. Appl Radiat Isot. 2014;91:64\u201370. https:\/\/doi.org\/10.1016\/j.apradiso.2014.04.021.","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"425_CR17","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/S0969-8043(99)00248-1","volume":"52","author":"E Hess","year":"2000","unstructured":"Hess E, Blessing G, Coenen HH, Qaim SM. Improved target system for production of high purity [18F]fluorine via the 18O(p,n)18F reaction. Appl Radiat Isot. 2000;52(6):1431\u201340. https:\/\/doi.org\/10.1016\/S0969-8043(99)00248-1.","journal-title":"Appl Radiat Isot"},{"key":"425_CR18","unstructured":"Heston TF, Tafti D. Nuclear medicine safety. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from:\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572108\/"},{"issue":"17","key":"425_CR19","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/jcm11175064","volume":"11","author":"MA Hoffmann","year":"2022","unstructured":"Hoffmann MA, M\u00fcller-H\u00fcbenthal J, Rosar F, Fischer N, von Eyben FE, Buchholz HG, et al. Primary staging of prostate cancer patients with [18F]PSMA-1007 PET\/CT compared with [68Ga]Ga-PSMA-11 PET\/CT. J Clin Med. 2022a;11(17):5064. https:\/\/doi.org\/10.3390\/jcm11175064.","journal-title":"J Clin Med"},{"issue":"6","key":"425_CR20","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/cancers14061479","volume":"14","author":"MA Hoffmann","year":"2022","unstructured":"Hoffmann MA, von Eyben FE, Fischer N, Rosar F, M\u00fcller-H\u00fcbenthal J, Buchholz HG, et al. Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET\/CT in restaging of prostate cancer patients with PSA relapse. Cancers (Basel). 2022b;14(6):1479. https:\/\/doi.org\/10.3390\/cancers14061479.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"425_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1470-2045(10)70198-4","volume":"11","author":"J Hugosson","year":"2010","unstructured":"Hugosson J, Carlsson S, Aus G, Bergdahl C, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(10)70198-4.","journal-title":"Lancet Oncol"},{"issue":"3","key":"425_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/jlcr.4013","volume":"66","author":"JA Ioppolo","year":"2023","unstructured":"Ioppolo JA, de Alvarez Eulate E, Cullen DR, Mohamed S, Morandeau L. Development of a high-performance liquid chromatography method for rapid radiochemical purity measurement of [18F]PSMA-1007, a PET radiopharmaceutical for detection of prostate cancer. J Labelled Comp Radiopharm. 2023;66(3):58\u201372. https:\/\/doi.org\/10.1002\/jlcr.4013.","journal-title":"J Labelled Comp Radiopharm"},{"issue":"2","key":"425_CR23","first-page":"227","volume":"53","author":"RS Israeli","year":"1993","unstructured":"Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53(2):227\u201330.","journal-title":"Cancer Res"},{"issue":"3","key":"425_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/ph14030188","volume":"14","author":"I Katzschmann","year":"2021","unstructured":"Katzschmann I, Marx H, Kopka K, Hennrich U. Development and validation of a GMP-compliant high-pressure liquid chromatography method for the determination of the chemical and radiochemical purity of [18F]PSMA-1007, a PET tracer for the imaging of prostate cancer. Pharmaceuticals (Basel). 2021;14(3):188. https:\/\/doi.org\/10.3390\/ph14030188.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"425_CR25","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1088\/1361-6498\/ac2a8c","volume":"41","author":"R Kollaard","year":"2021","unstructured":"Kollaard R, Zorz A, Dabin J, Covens P, Cooke J, Crabb\u00e9 M, et al. Review of extremity dosimetry in nuclear medicine. J Radiol Prot. 2021;41(4):R60\u201386. https:\/\/doi.org\/10.1088\/1361-6498\/ac2a8c.","journal-title":"J Radiol Prot"},{"issue":"4","key":"425_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/1097-0045(20001201)45:4<350::AID-PROS10>3.0.CO;2-U","volume":"45","author":"RG Lapidus","year":"2000","unstructured":"Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. 2000;45(4):350\u20134. https:\/\/doi.org\/10.1002\/1097-0045(20001201)45:4%3c350::AID-PROS10%3e3.0.CO;2-U.","journal-title":"Prostate"},{"issue":"1","key":"425_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41181-021-00150-z","volume":"6","author":"C Maisto","year":"2021","unstructured":"Maisto C, Morisco A, de Marino R, Squame E, Porfidia V, D\u2019Ambrosio L, et al. On site production of [18F]PSMA-1007 using different [18F]fluoride activities: practical, technical and economical impact. EJNMMI Radiopharm Chem. 2021;6(1):36. https:\/\/doi.org\/10.1186\/s41181-021-00150-z.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"425_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00345-020-03344-3","volume":"39","author":"E Mena","year":"2021","unstructured":"Mena E, Black PC, Rais-Bahrami S, Gorin M, Allaf M, Choyke P. Novel PET imaging methods for prostate cancer. World J Urol. 2021;39(3):687\u201399. https:\/\/doi.org\/10.1007\/s00345-020-03344-3.","journal-title":"World J Urol"},{"issue":"1","key":"425_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-020-00101-0","volume":"5","author":"S Naka","year":"2020","unstructured":"Naka S, Watabe T, Kurimoto K, Uemura M, Soeda F, Neels OC, et al. Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. EJNMMI Radiopharm Chem. 2020;5(1):18. https:\/\/doi.org\/10.1186\/s41181-020-00101-0.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"suppl 1","key":"425_CR30","first-page":"402","volume":"59","author":"O Neels","year":"2018","unstructured":"Neels O, Martin R, Cardinale J, Smits R, Schaefer M, Hoepping A, et al. GMP-compliant fully automated single-step radiosynthesis of [18F]PSMA-1007 using SPE cartridge purification. J Nucl Med. 2018;59(suppl 1):402.","journal-title":"J Nucl Med"},{"issue":"5","key":"425_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.apradiso.2005.11.010","volume":"64","author":"JA Nye","year":"2006","unstructured":"Nye JA, Avila-Rodriguez MA, Nickles RJ. A grid-mounted niobium body target for the production of reactive [18F]fluoride. Appl Radiat Isot. 2006;64(5):536\u20139. https:\/\/doi.org\/10.1016\/j.apradiso.2005.11.010.","journal-title":"Appl Radiat Isot"},{"issue":"1","key":"425_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874471012666190729151540","volume":"13","author":"S Pastorino","year":"2020","unstructured":"Pastorino S, Riondato M, Uccelli L, Giovacchini G, Giovannini E, Duce V, et al. Toward the discovery and development of PSMA targeted inhibitors for nuclear medicine applications. Curr Radiopharm. 2020;13(1):63\u201379. https:\/\/doi.org\/10.2174\/1874471012666190729151540.","journal-title":"Curr Radiopharm"},{"key":"425_CR33","unstructured":"PETtrace\u2122 800 cyclotron series. Data sheet. GE Healthcare; 2024. Available from:\u00a0https:\/\/www.gehealthcare.com\/products\/cyclotrons\/pettrace-800-cyclotron-system."},{"issue":"5","key":"425_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/imj.12407","volume":"44","author":"C Pezaro","year":"2014","unstructured":"Pezaro C, Woo HH, Davis ID. Prostate cancer: measuring PSA. Intern Med J. 2014;44(5):433\u201340. https:\/\/doi.org\/10.1111\/imj.12407.","journal-title":"Intern Med J"},{"issue":"5","key":"425_CR35","first-page":"395","volume":"11","author":"L Saule","year":"2021","unstructured":"Saule L, Radzina M, Liepa M, Skagers A, Rains A, Nakurte I, et al. Diagnostic scope of 18F-PSMA-1007 PET\/CT: comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence. Am J Nucl Med Mol Imaging. 2021;11(5):395\u2013405.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"12","key":"425_CR36","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2967\/jnumed.108.057026","volume":"49","author":"K Serdons","year":"2008","unstructured":"Serdons K, Verbruggen A, Bormans G. The presence of ethanol in radiopharmaceutical injections. J Nucl Med. 2008;49(12):2071. https:\/\/doi.org\/10.2967\/jnumed.108.057026.","journal-title":"J Nucl Med"},{"issue":"1","key":"425_CR37","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"425_CR38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4274\/mirt.galenos.2023.47550","volume":"32","author":"\u00c7 Soydal","year":"2023","unstructured":"Soydal \u00c7, Demir B, S\u00fct\u00e7\u00fc G, Araz M, K\u00fc\u00e7\u00fck N\u00d6. Comparison of 68Ga-PSMA PET\/CT and 18F-PSMA PET\/CT of a patient with prostate cancer recurrence on urinary bladder wall. Mol Imaging Radionucl Ther. 2023;32(2):150\u20132. https:\/\/doi.org\/10.4274\/mirt.galenos.2023.47550.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"9","key":"425_CR39","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","volume":"19","author":"H Van Poppel","year":"2022","unstructured":"Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol. 2022;19(9):562\u201372. https:\/\/doi.org\/10.1038\/s41585-022-00638-6.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"425_CR40","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0969-8043(99)00254-7","volume":"53","author":"SK Zeisler","year":"2000","unstructured":"Zeisler SK, Becker DW, Pavan RA, Moschel R, R\u00fchle H. A water-cooled spherical niobium target for the production of [18F]fluoride. Appl Radiat Isot. 2000;53(3):449\u201353. https:\/\/doi.org\/10.1016\/S0969-8043(99)00254-7.","journal-title":"Appl Radiat Isot"},{"issue":"2","key":"425_CR41","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ol.2016.4699","volume":"12","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Zhu Z, Yang D, Fan W, Wang J, Li X, et al. Preparation and affinity identification of glutamic acid-urea small molecule analogs in prostate cancer. Oncol Lett. 2016;12(2):1001\u20136. https:\/\/doi.org\/10.3892\/ol.2016.4699.","journal-title":"Oncol Lett"},{"key":"425_CR42","doi-asserted-by":"publisher","first-page":"585213","DOI":"10.3389\/fonc.2020.585213","volume":"10","author":"X Zhou","year":"2021","unstructured":"Zhou X, Li YC, Wang Y, Zhang Y, Li M, Zhang Y, et al. Intra-individual comparison of 18F-PSMA-1007 and 18F-FDG PET\/CT in the evaluation of patients with prostate cancer. Front Oncol. 2021;10:585213. https:\/\/doi.org\/10.3389\/fonc.2020.585213.","journal-title":"Front Oncol"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00425-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00425-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:38:22Z","timestamp":1771328302000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00425-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00425-3","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Given the nature of the study, no specific ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}